Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats
| Autor: | Gonca Cayir Keles, Pınar Naile Gürgör, Burcu Ozkan Cetinkaya, Bulent Ayas |
|---|---|
| Přispěvatelé: | Ondokuz Mayıs Üniversitesi |
| Rok vydání: | 2008 |
| Předmět: |
Male
Periodontium Time Factors Alveolar Bone Loss Drug Evaluation Preclinical Dentistry Osteoclasts Cell Count Neovascularization Placebos Random Allocation Bone Density Bone Marrow Osteogenesis Image Processing Computer-Assisted Medicine periodontitis Bone Density Conservation Agents osteonecrosis Osteonecrosis Etidronic Acid Resorption Dose–response relationship Risedronic acid Periodontics risedronate medicine.symptom Risedronic Acid medicine.drug medicine.medical_specialty Urology Neovascularization Physiologic Periodontal Attachment Loss Alveolar Process Animals Rats Wistar Periodontitis bisphosphonates Dental alveolus Osteoblasts Dose-Response Relationship Drug business.industry medicine.disease Rats Osteopenia animal studies Blood Vessels Angiogenesis business |
| Zdroj: | Journal of periodontology. 79(10) |
| ISSN: | 0022-3492 |
| Popis: | WOS: 000260142100017 PubMed: 18834251 Background: The present study was designed to evaluate the effects of risedronate, one of the most potent bisphosphonates, on alveolar bone resorption and angiogenesis in rats with experimental periodontitis to identify dose-response curves and treatment durations that can be therapeutic for periodontal therapy versus those associated with osteonecrosis of the jaws. Methods: Thirty-five rats, 25 with experimental periodontitis (groups I through 5) and 10 with healthy periodontium (groups 6 and 7), were divided into seven equal groups: group I received no treatment; groups 2 and 3 received risedronate, 0.1 and 1 mg/kg, respectively, for 3 weeks; groups 4 and 5 received risedronate, 0.1 and I mg/kg, respectively, for 8 weeks; and groups 6 and 7 received 0.9% NaCl for 3 and 8 weeks, respectively. Animals in groups 2 through 7 were administered treatment 5 days per week. After histologic processing, histomorphometric and stereologic analyses were carried out to estimate the number of blood vessels (NBV) and the volumetric densities of bone (Vb), marrow (Vm), osteoblasts (Vob), and osteoclasts (Voc). Results: A total of 0.1 and I mg/kg risedronate for 3 weeks (groups 2 and 3) significantly increased Vb and Vob and decreased Vm more prominently in group 2 (P 0.05). No significant decrease in Voc was found in drug -administered groups compared to group I (P >0.05). A significant decrease in NBV (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text